Masi, L.
Marini, F.
Franceschelli, F.
Leoncini, G.
Cianferotti, L.
Cioppi, F.
Giusti, F.
Marcucci, G.
Gronchi, G.
Brandi, M. L. http://orcid.org/0000-0002-8741-0592
Funding for this research was provided by:
Alexion Pharmaceuticals (MIG-100186)
Article History
Received: 25 June 2020
Accepted: 15 February 2021
First Online: 7 June 2021
Declarations
:
: The authors declare that they have no conflict of interest.
: Patients included in this study underwent genetic screening of the <i>ALPL</i> gene and the collection of bone and HPP-related clinical and biochemical data based on their diagnostic and clinical management, independently from the present study, performed after the signing of a specific informed consent form for genetic diagnosis, previously approved by the Internal Review Board of the “Azienda Ospedaliero-Universitaria Careggi, Firenze.”
: Each patient signed a specific informed consent form for the execution of the diagnostic <i>ALPL</i> genetic test, which was part of his/her normal diagnostic management, independent from the present study. All data in this manuscript were analyzed anonymously.
: This manuscript does not contain any individual person’s data in any form. All data were analyzed anonymously and published exclusively as aggregates.